chartexchange

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

PR Newswire | Oct 14, 2026 4:30 PM EDT

Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and commercialization, as it plans to initiate the pivotal Phase 3 trial of relcobatinib before year-end...

Read original article